Membranoproliferative glomerulonephritis medical therapy

Revision as of 20:17, 2 August 2018 by Aditya Ganti (talk | contribs)
Jump to navigation Jump to search


Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis medical therapy

CDC on Membranoproliferative glomerulonephritis medical therapy

Membranoproliferative glomerulonephritis medical therapy in the news

Blogs on Membranoproliferative glomerulonephritis medical therapy

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3] Jogeet Singh Sekhon, M.D. [4] Syed Ahsan Hussain, M.D.[5]

Overview

The optimal therapy for membranoproliferative glomerulonephritis depends on underlying etiology. In infectious and haematological etiology treating the underlying infection will result in resolution of membranoproliferative glomerulonephritis.For autoimmune etiology immunosuppressive agents are given.The treatment also includes antihypertensive therapy, anticoagulation therapy and anti-lipid therapy for nephrotic syndrome.

Medical Therapy

  • Pharmacologic therapy is recommended for patients of membranoproliferative glomerulonephritis.[1]>[2][3][4]

.

1. Patients with autoimmune etiology

  • 1.1 Immunosuppressive therapy:
  • 2. Treatment for nephrotic sydnrome:

References

  1. Bomback AS, Fervenza FC (2018). "Membranous Nephropathy: Approaches to Treatment". Am J Nephrol. 47 Suppl 1: 30–42. doi:10.1159/000481635. PMID 29852477.
  2. Waldman M, Austin HA (2012). "Treatment of idiopathic membranous nephropathy". J Am Soc Nephrol. 23 (10): 1617–30. doi:10.1681/ASN.2012010058. PMC 3458460. PMID 22859855.
  3. Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
  4. Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L (April 2005). "The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis". Clin. Nephrol. 63 (4): 245–9. PMID 15847250.

Template:WH Template:WS